JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M111217200 on February 20, 2002

J. Biol. Chem., Vol. 277, Issue 18, 15523-15529, May 3, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/18/15523    most recent
M111217200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Willets, J. M.
Right arrow Articles by Nahorski, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Willets, J. M.
Right arrow Articles by Nahorski, S. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Endogenous G Protein-coupled Receptor Kinase 6 Regulates M3 Muscarinic Acetylcholine Receptor Phosphorylation and Desensitization in Human SH-SY5Y Neuroblastoma Cells*

Jonathon M. WilletsDagger, R. A. John Challiss, and Stefan R. Nahorski

From the Department of Cell Physiology and Pharmacology, University of Leicester, University Road, Leicester, LE1 9HN, United Kingdom

Received for publication, November 26, 2001, and in revised form, January 25, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have previously shown that overexpression of G protein-coupled receptor kinase 6 (GRK6) enhanced the phosphorylation and desensitization of the endogenously expressed M3 muscarinic acetylcholine (mACh) receptor in human SH-SY5Y neuroblastoma cells. In this study we have examined the potential role of endogenous GRK6 in the regulation of M3 mACh receptor by blocking its action through the introduction of a kinase-dead, dominant-negative GRK6 (K215RGRK6). K215RGRK6 expression inhibited methacholine-stimulated M3 mACh receptor phosphorylation by 50% compared with plasmid transfected control cells. Guanosine-5'-O-(3-[35S]thio)triphosphate binding and immunoprecipitation studies, conducted after agonist pretreatment (3 min), indicated that M3 mACh receptor-Galpha q/11 uncoupling was attenuated by 50% in cells expressing K215RGRK6 when compared with control cells. In contrast, expression of the related dominant-negative kinase K215RGRK5 had no effect on M3 mACh receptor phosphorylation or uncoupling. Time course studies also showed that agonist-stimulated [3H]inositol phosphate accumulations were more sustained in cells expressing K215RGRK6 compared with control and K215RGRK5-expressing cells, whereas K215RGRK6 expression had no effect on the phospholipase C response to direct stimulation of G proteins with AlF<UP><SUB><RM><IT>4</IT></RM></SUB><SUP><RM><IT>−</IT></RM></SUP></UP>. The ability of K215RGRK6 to inhibit agonist-mediated M3 mACh receptor phosphorylation and G protein uncoupling suggests that endogenous GRK6 mediates, at least in part, M3 mACh receptor desensitization in the SH-SY5Y cell line.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The majority of G protein-coupled receptors desensitize when stimulated continuously or repetitively. This process can be initiated via phosphorylation of the receptor, which leads to receptor-G protein uncoupling (1-3) and reduced receptor signaling to downstream pathways. Second messenger-regulated kinases, such as PKC1 (4) and cAMP-dependent protein kinase (5, 6), and specific G protein-coupled receptor kinases (GRKs) (7, 8) have been implicated in G protein-coupled receptor desensitization through phosphorylation of serine and threonine residues within the third intracellular loop or C-terminal tail of G protein-coupled receptors. Upon agonist stimulation, the human M3 muscarinic acetylcholine (mACh) receptor is rapidly phosphorylated (9), and a number of different kinases have been implicated in this process, including PKC (10, 11) and casein kinase 1alpha (CK1alpha ) (12). However, agonist-stimulated receptor phosphorylation by either CK1alpha or PKC does not appear to mediate rapid desensitization of the M3 mACh receptor (10-12).

More recently, we have examined the potential involvement of GRKs in the desensitization of the M3 mACh receptor endogenously expressed in the SH-SY5Y cell line (13). This human neuroblastoma expresses GRKs 3 and 6, and overexpression of GRK3 and GRK6 leads to enhanced M3 mACh receptor phosphorylation and reduced activation of phospholipase C (PLC). However, only GRK6 overexpression enhanced uncoupling of the receptor from Galpha q/11 assessed by a [35S]GTPgamma S binding/immunoprecipitation protocol. In contrast, only GRK3 overexpression suppressed AlF<UP><SUB>4</SUB><SUP>−</SUP></UP> activation of PLC (13). These data strongly support an action of GRK3 independent of phosphorylation, possibly via direct binding to activated Galpha q/11 and/or free Gbeta gamma subunits, but highlight a potential role for GRK6 via receptor phosphorylation and uncoupling of Galpha q/11.

Although GRK6 overexpression can be shown to enhance the M3 mACh receptor desensitization process in SH-SY5Y cells, this experimental approach is unable to resolve whether endogenous GRK6 contributes to M3 mACh receptor regulation. Therefore, in an attempt to block the actions of endogenous GRK6, we have introduced a kinase-dead, dominant-negative mutant form of GRK6, created by introducing a K215R point mutation into the ATP-binding domain, into SH-SY5Y cells to create cell lines stably expressing this construct. Using this approach we have shown that K215RGRK6 expression inhibits the phosphorylation and subsequent desensitization of the M3 mACh receptor. Our data suggest that GRK6 plays a significant role in the desensitization of the endogenously expressed M3 mACh receptor in human SH-SY5Y neuroblastoma cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture and Creation of Stably Transfected Dominant-negative GRK Cell Lines-- SH-SY5Y human neuroblastoma cells were cultured in minimal essential medium containing 5% fetal and 5% new born calf serum, penicillin (100 units/ml), streptomycin (100 µg/ml), and fungizone (2.5 µg/ml) (Invitrogen). All of the cells were maintained at 37 °C in humidified conditions under 5% CO2. Wild-type SH-SY5Y cells were transfected with either pcDNA3 alone or human dominant-negative GRK5 or GRK6, both with a single point mutation at K215R, cloned into pcDNA3 at BamHI and XbaI, or EcoRI for GRKs 5 (14) and 6, respectively (both kindly provided by E. Kelly, University of Bristol, Bristol, UK), using FuGENE 6 according to the manufacturer's instructions. After 48 h, geneticin (300 µg/ml) was added to the cells. The surviving colonies were selected and expanded into cell lines.

Western Blotting-- The cells were lysed and subjected to electrophoretic separation exactly as described previously (15, 16). The separated protein was transferred to nitrocellulose, and GRK expression was detected using anti-rabbit polyclonal IgG antibodies (1:1000 dilution) specific for GRK2, GRK3, GRK5, or GRK6 (Santa Cruz Biotechnology). Galpha q/11 expression was detected using an anti-rabbit polyclonal IgG (Santa Cruz Biotechnology). CK1alpha was detected using an anti-rabbit polyclonal as described previously (12). Protein expression was determined by the addition of ECL reagent (Amersham Biosciences), according to the manufacturer's instructions and exposure to Hyperfilm (Amersham Biosciences).

Determination of mACh Receptor Number and Receptor Internalization-- The Bmax and Kd values were determined by N-methyl-[3H]scopolamine ([3H]NMS; Amersham Biosciences) saturation binding analysis of SH-SY5Y cell monolayers grown to confluence in 24-well plates as described previously (13).

M3 mACh receptor internalization was assessed after treatment with either vehicle or methacholine (100 µM) for 0-60 min at 37 °C, prior to intensive washing (four times with 1 ml of ice-cold Krebs buffer, pH 7.4). [3H]NMS-binding sites were determined as above using a single saturating concentration (5 nM) of [3H]NMS for 18 h at 4 °C. Nonspecific binding was determined by the addition of excess atropine (20 µM). Receptor internalization was determined as the percentage of loss of specific [3H]NMS-binding sites after methacholine treatment when compared with vehicle-treated controls.

M3 mACh Receptor Phosphorylation-- The effect of K215RGRK6 and K215RGRK5 expression on the phosphorylation of endogenously expressed M3 muscarinic receptors was assessed by the method of Tobin and Nahorski (9). Briefly, either plasmid control or cells expressing either K215RGRK6 or K215RGRK5 were seeded into 6-well culture plates. Confluent cells were loaded with [32P]orthophosphate (5 µCi/ml; Amersham Biosciences) in phosphate-free Krebs buffer, pH 7.4, for 1 h prior to agonist challenge (methacholine, 100 µM). After 3 min, the agonist was removed, and the cells were solubilized, immunoprecipitated, and electrophoretically resolved as described previously (13). Autoradiograms were documented and quantified using the GeneGenius system and software (Syngene, Cambridge, UK).

Casein Phosphorylation-- Any potential kinase activity of dominant-negative GRK5 and GRK6 was assessed by measuring their ability to phosphorylate the substrate alpha -casein as described previously (13).

Measurement of Total [3H]Inositol Phosphate Accumulation-- Either plasmid control or cells expressing K215RGRK5 or K215RGRK6 were seeded into 24-well plates at ~50% confluency. After 24 h, the cells were incubated in the presence of [3H]inositol (1 µCi/ml) in geneticin-free medium for a further 24 h. Confluent cell monolayers were then washed twice with Krebs buffer (118.6 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 4.2 mM NaHCO3, 10 mM HEPES, 11.7 mM glucose, and 1.3 mM CaCl2, pH 7.4) and incubated for 15 min at 37 °C. LiCl (final concentration, 10 mM) was added to each well for 10 min prior to the addition of methacholine. Reaction termination, sample neutralization, and separation of the [3H]inositol phosphate fraction (containing inositol mono-, bis-, and tris-phosphates) were performed as described previously (17).

Assessment of M3 mACh receptor Galpha q/11 Coupling by [35S]GTPgamma S Binding-- Plasmid control or dominant-negative GRK-expressing cells were grown in 80-cm2 cell culture flasks until confluent. The cells were then harvested in 10 mM HEPES, pH 7.4, 0.2% (v/v) EDTA, 0.9% (v/v) NaCl. After centrifugation the cells were resuspended in Krebs buffer, pH 7.4, at 37 °C for 15 min prior to the addition of either vehicle or MCh (100 µM). After 3 min, excess ice-cold Krebs buffer (50 ml) was added, and the cells were pelleted at 1000 × g for 5 min. The cell pellets were then resuspended in 30 ml of 20 mM HEPES, pH 7.4, 10 mM EDTA and homogenized at maximum speed for 30 s using a PT210 Polytron. The resulting suspension was centrifuged at 20,000 × g for 15 min. The pellet was resuspended in 30 ml of 20 mM HEPES, pH 7.4, 0.1 mM EDTA and centrifuged for a further 15 min at 20,000 × g. The resulting pellet was resuspended at 1 mg/ml of protein and stored at -80 °C until required.

[35S]GTPgamma S binding and immunoprecipitation were performed as described previously (18, 19). Briefly, 50 µg of membranes were added to 1 nM [35S]GTPgamma S (PerkinElmer Life Sciences), 1 µM GDP, 100 µM ±methacholine in assay buffer (100 mM HEPES, 100 mM NaCl, 10 mM MgCl2, pH 7.4) and incubated for 2 min at 30 °C. Nonspecific binding was determined by inclusion of 10 µM GTPgamma S. Termination, solubilization, and Galpha q/11-specific immunoprecipitation were performed exactly as described previously (13). Desensitization was determined as a reduction in [35S]GTPgamma S binding after pretreatment with methacholine and expressed as a percentage of the response found when compared with a nonpretreated matched control. In addition to desensitization experiments, M3 mACh receptor activation of Galpha q/11 was assessed in nonpretreated cell membranes via generation of methacholine (300 nM to 1 mM) concentration-response curves.

Data Analysis-- All concentration-response curves were fitted, and the EC50 values were determined using nonlinear regression analysis (GraphPad Prism 3). All data were analyzed using one- or two-way analysis of variance (Microsoft Excel version 5). Significance was accepted when p < 0.05.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Creation of Stable Dominant-negative GRK Cell Lines-- Transfection of wild-type SH-SY5Y neuroblastoma cells with either K215RGRK6 or K215RGRK5 and selection with geneticin (300 µg/ml) yielded several surviving colonies, which were expanded into cell lines. Two clones that expressed K215RGRK6 and that were matched with plasmid controls for receptor number based on [3H]NMS binding were selected for further study (named D1 and D5; Fig. 1A). Estimation of the level of K215RGRK6 expression was determined by serial dilution of cell lysates and subsequent Western blotting, indicating ~30-fold greater levels than endogenous GRK6 expression (data not shown). In an attempt to examine the specificity of the effects of K215RGRK6, a single clone expressing the closely related K215RGRK5 (D2; Fig. 1B) was chosen for some experiments. The level of overexpression of K215RGRK5 was difficult to assess because there was no detectable endogenous GRK5 in SH-SY5Y cells. To determine whether K215RGRK6 lacked kinase activity (i.e. was kinase-dead), HEK293 cells were transiently transfected with empty vector, GFP-tagged wt-GRK6, or GFP-tagged K215RGRK6. After 48 h the kinases were immunoprecipitated with either GFP polyclonal or wt-GRK6 antibodies. Kinase activity was assessed by addition of dephosphorylated alpha -casein in the presence of [gamma -32P]ATP (as described under "Experimental Procedures"). No phosphorylation of alpha -casein was detected after transfection with empty vector, followed by immunoprecipitation with GFP antibody (Fig. 1C). As expected, enhanced alpha -casein phosphorylation was detected after transfection of GFP-tagged GRK6. Furthermore, a slight phosphorylation of alpha -casein was detected after immunoprecipitation of endogenously expressed GRK6 from nontransfected HEK293 cells. In contrast, alpha -casein phosphorylation was not evident in the presence of K215RGRK6.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 1.   Determination of expression and activity in SH-SY5Y cells stably transfected with either K215RGRK6 or K215RGRK5. Whole cell lysates were subjected to SDS-PAGE followed by Western transfer and immunoblotting with polyclonal antibodies recognizing either GRK6 (A) or GRK5 (B). In A and B, lysates were corrected for protein with 40 µg loaded per lane. A, lanes 1 and 3, clones P1 and P3 (plasmid control), respectively; lanes 2 and 4, clones D5 and D1, respectively (K215RGRK6-expressing). B, lane 1, clone P3 (plasmid control); lane 2, clone D2 (K215RGRK5-expressing). C, assessment of GRK function. HEK293 cells were transfected with empty vector (lanes 1 and 3), GFP-tagged GRK6 (lanes 2 and 5), or GFP-tagged K215RGRK6 (lanes 4 and 6). The cells were lysed and mixed with GFP polyclonal antibody (lanes 1, 2, and 4-6) to immunoprecipitate GFP-tagged kinases, before the addition of [gamma -32P]ATP and dephosphorylated alpha -casein for 10 min at 37 °C. GRKs were removed from the reaction mix by centrifugation, and the resultant supernatant was separated by SDS-PAGE. alpha -Casein phosphorylation was determined by autoradiography. Lane 3 shows the degree of alpha -casein phosphorylation seen after immunoprecipitation of endogenous wt-GRK6, by wt-GRK6 polyclonal antibody from HEK293 cells. The data are representative of three separate experiments.

Effects of K215RGRK5 or K215RGRK6 on Expression of Endogenous GRKs and CK1alpha -- In an attempt to determine whether overexpression of K215RGRK5 or K215RGRK6 altered the expression of other endogenously expressed kinases, we first blotted all the clones used in this study for GRKs 2, 3, 5, and 6, as well as CK1alpha (Fig. 2). Overexpression of K215RGRK5 had no effect on the expression of any of the kinases studied. Furthermore, K215RGRK6 overexpression had no effect on GRK2, GRK3, GRK5, or CK1alpha expression in any of the cell lines. However, it was not possible to assess whether K215RGRK6 altered the expression of endogenous GRK6 because both K215RGRK6 and wild-type GRK6 are not distinguishable with the antibody used (Fig. 2D).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 2.   Overexpression of K215RGRK5 or K215RGRK6 does not effect the expression of endogenously expressed GRKs or CK1alpha . Whole cell lysates were subjected to SDS-PAGE followed by Western transfer and immunoblotting with polyclonal antibodies recognizing either GRK2 (A), GRK3 (B), GRK5 (C), GRK6 (D), and CK1alpha (E) from P1 (lane 1), P3 (lane 2), D1 (lane 3), D5 (lane 4), and D2 (lane 5) cells. In all cases lysates were corrected for protein with 40 µg loaded per lane. The data are representative of three separate experiments.

Determination of M3 Receptor Number-- Whole cell binding studies were undertaken using [3H]NMS to determine whether expression of dominant-negative constructs affected M3 mACh receptor expression. The data obtained for Bmax and KD indicated that expression of either K215RGRK6 or K215RGRK5 had no significant effect on M3 mACh receptor expression (Table I). Moreover, receptor expression levels did not alter with passage (data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Whole cell [3H]NMS saturation binding to determine M3 mACh receptor expression in plasmid control, K215RGRK6, and K215RGRK5 expressing clones
The Bmax and KD values were determined using nonlinear regression analysis and curve-fitting programs of GraphPad Prism 3. The data are expressed as the means of specific binding ± S.E. for five or six separate experiments.

M3 mACh Receptor Phosphorylation-- The effects of K215RGRK6 expression on methacholine-stimulated (100 µM) M3 mACh receptor phosphorylation was examined in clones D1 and D5. As shown in Fig. 3 (A and B), after 3 min of agonist exposure a robust phosphorylation was observed in the plasmid control cell lines (P1 and P3). In contrast, M3 mACh receptor phosphorylation was reduced by ~50% in cells expressing K215RGRK6. Furthermore, expression of K215RGRK5 had no effect on agonist-stimulated M3 mACh receptor phosphorylation (Fig. 3C). Densitometric analysis confirmed that K215RGRK6 had no effect on basal M3 mACh receptor phosphorylation. However, K215RGRK6 significantly (p < 0.01) reduced agonist-stimulated M3 mACh receptor phosphorylation by 50 and 43% for D1 compared with P3 and for D5 compared with P1 clones, respectively (Fig. 4). Furthermore, expression of K215RGRK6 did not affect PKC-mediated M3 mACh receptor phosphorylation stimulated by phorbol 12,13-dibutyrate (PDBu) (1 µM, 3 min; Fig. 3D).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of K215RGRK6 expression on agonist-stimulated M3 mACh receptor phosphorylation. Confluent plasmid control and K215RGRK6- or K215RGRK5-expressing cells were loaded with [32P]orthophosphate (5 µCi/ml) in phosphate-free Krebs buffer, pH 7.4. After 1 h cells were challenged with MCh (100 µM) for 3 min, prior to lysis and immunoprecipitation of the M3 mACh receptors with a specific M3 mACh receptor antibody. The samples were processed as described under "Experimental Procedures" and corrected for receptor expression before quantification of 32P receptor incorporation by autoradiography. Representative autoradiograms are shown for M3 mACh receptor phosphorylation in P1 (lanes 1-3) and D5 (lanes 4-6) cells (A), and P3 (lanes 1-3) and D1 (lanes 4-6) cells (B), and P3 (lanes 1-3) and D2 (lanes 4-6) (C). PKC-mediated M3 mACh receptor phosphorylation was also examined in PDBu-treated P3 (lanes 1-3) and D1 (lanes 4-6) cells (D); lanes 1 and 3, basals; lanes 2 and 5, PDBu (1 µM, 3 min); lanes 3 and 6, pretreatment with Ro 31-8220 (10 µM, 15 min) followed by PDBu (1 µM, 3 min).


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 4.   Analysis of the effects of K215RGRK6 expression on MCh-stimulated M3 mACh receptor phosphorylation in two clones (D1 and D5). The samples prepared as described under "Experimental Procedures" and in the legend to Fig. 2 were subjected to densitometric analysis using the GeneGenius image analysis system and software (Syngene). M3 mACh receptor phosphorylation is shown as basal (open bars) and after methacholine (100 µM) stimulation (3 min, black bars). The data are expressed as the means ± S.E. of four separate experiments. Expression of K215RGRK6 significantly inhibited methacholine-stimulated M3 mACh receptor phosphorylation when compared with plasmid controls. *, p < 0.01; **, p < 0.001.

Assessment of M3 mACh Receptor Desensitization by [35S]GTPgamma S Binding-- To determine whether the inhibition of agonist-stimulated M3 mACh receptor phosphorylation observed with K215RGRK6 expression had a subsequent effect on receptor function, we examined the direct interaction of the M3 mACh receptor and Galpha q/11 at the point of receptor catalyzed GTP/GDP exchange. Thus, we have used agonist-stimulated [35S]GTPgamma S binding followed by immunoprecipitation of Galpha q/11 in a membrane preparation (see "Experimental Procedures").

First, we assessed whether expression of K215RGRK6 had any effects on acute M3 mACh receptor-Galpha q/11 interaction. Concentration-response curves in membranes from nonpretreated K215RGRK6-expressing clones, undertaken at 2 min, the optimal time point for M3 mACh receptor-Galpha q/11 activation (13, 19), showed binding identical to that seen in controls (Fig. 5A). However, as described previously (11, 13), pretreatment of intact cells with MCh (100 µM) for 3 min leads to reduced agonist-stimulated [35S]GTPgamma S binding to immunoprecipitated Galpha q/11 in the subsequent membrane assay (Fig. 5B). Plasmid control cells (P1 and P3) showed 59 (D1 versus P3) and 46% (D5 versus P1) less M3 mACh receptor-Galpha q/11 coupling when compared with nonpretreated controls. In contrast, the degree of receptor-Galpha q/11 uncoupling was inhibited by 50% with K215RGRK6 expression (Fig. 5B). Interestingly, despite agonist pretreatment, expression of K215RGRK5 had no effect on M3 mACh receptor-Galpha q/11 uncoupling (Fig. 5B). These effects were not due to a loss of membrane-associated Galpha q/11 because total Galpha q/11 immunoreactivity in the membrane fraction was unaltered after 3 min of pretreatment (Fig. 5C).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of K215RGRK6 expression on M3 mACh receptor-Galpha q/11 coupling in SH-SY5Y cells. A, Concentration-response curves for methacholine-stimulated (300 nM to 1 mM) M3 mACh receptor-Galpha q/11 recruitment in plasmid control (P3, black-square) and cells expressing K215RGRK6 (D1, ; D5, ), as measured by [35S]GTPgamma S binding and Galpha q/11 immunoprecipitation from nonpretreated cell membranes. [35S]GTPgamma S binding was conducted at 30 °C and at the peak of Galpha q/11 recruitment, 2 min. The data are expressed as the means ± S.E. (in cpm) and are representative of three separate experiments. Basal values were as follows: P3, 561 ± 86 cpm; D1, 554 ± 87 cpm; D5, 511 ± 81 cpm (n = 3). B, effect of K215RGRK6 and K215RGRK5 (D2) expression on methacholine-stimulated M3 mACh receptor uncoupling. Intact plasmid control (P1 and P3), K215RGRK6 (D1 and D5), or K215RGRK5-expressing cells were pretreated with methacholine (100 µM) for 3 min at 37 °C. After pretreatment, the cells were washed and converted into membranes, prior to a second methacholine (100 µM) challenge, for 2 min at 30 °C, in the presence of [35S]GTPgamma S. Methacholine-stimulated [35S]GTPgamma S binding to Galpha q/11 after pretreatment was determined as described under "Experimental Procedures," and the data were expressed as fold over basal. M3 mACh receptor uncoupling was determined as the decrease in [35S]GTPgamma S binding to Galpha q/11 after methacholine pretreatment when compared with the value obtained in a nonpretreated control (i.e. 0 = no uncoupling, whereas 100% = total receptor uncoupling). The data shown are the means ± S.E. of three separate experiments. K215RGRK6 expression significantly inhibited methacholine-stimulated M3 mACh receptor uncoupling when compared with plasmid control and K215RGRK5 overexpressing cells. **, p < 0.001. Basal values were as follows: P3, 812 ± 35 cpm; D1, 755 ± 90 cpm; D5, 602 ± 33 cpm; D2, 805 ± 58 cpm (for six to eight separate experiments). C, effects of methacholine (100 µM) pretreatment on Galpha q/11 membrane association. The data shown are a representative immunoblot indicating the levels of membrane-bound Galpha q/11 in plasmid control (P3) or K215RGRK6-expressing (D1) cells, either in the absence or presence of MCh pretreatment. Lane 1, P3 cells, no methacholine pretreatment; lane 2, MCh-pretreated P3 cells (100 µM, 3 min, 37 °C); lane 3, D1 cells, no MCh pretreatment; lane 4, MCh-pretreated D1 cells (100 µM, 3 min, 37 °C).

Assessment of Phospholipase C Activity-- To further study the effects of GRK6 on M3 mACh receptor regulation, we examined the effects of K215RGRK6 on PLC activity using total [3H]inositol phosphate accumulation. Time course studies indicated that clones expressing K215RGRK6 produced significantly (p < 0.01) greater [3H]inositol phosphate accumulations than plasmid controls matched for receptor number (Fig. 6, A and B). In addition, concentration-response curves to MCh produced after 3 min indicate that expression of K215RGRK6 enhanced [3H]inositol phosphate accumulation when compared with plasmid control cells (Fig. 7). Interestingly, expression of the structurally similar dominant-negative kinase K215RGRK5 had no effect on [3H]inositol phosphate accumulation (Fig. 6C). In addition, [3H]inositol phosphate accumulation was similar in all clones after direct stimulation of Galpha q/11 with AlF<UP><SUB>4</SUB><SUP>−</SUP></UP> for 20 min (P3, 2873 ± 44; D1, 3121 ± 147; P1, 2754 ± 133; and D5, 3617 ± 768 dpm ± S.E., after subtraction of basal values for three separate experiments).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of dominant-negative GRK expression on MCh (100 µM) stimulated [3H]inositol phosphate accumulation in either. A, P3 (plasmid control, black-square), D1 (K215RGRK6-expressing, ), or GRK6/24 (GRK6-overexpressing, ) cells; B, P1 (plasmid control, black-square) or D5 (K215RGRK6-expressing, ) cells; C, P3 (plasmid control, black-square) or D2 (K215RGRK5-expressing, ) cells. [3H]Inositol phosphate accumulation was determined as described under "Experimental Procedures." The data are expressed as the means ± S.E. for three to five independent experiments. [3H]Inositol phosphate accumulation was significantly (p < 0.01, by two-way analysis of variance) increased in cells expressing K215RGRK6 when compared with plasmid control and K215RGRK5-expressing cells.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7.   Methacholine concentration-response curves in plasmid control or cells expressing either K215RGRK6 or GRK6. [3H]Inositol phosphate accumulation was determined as described under "Experimental Procedures." The data are expressed as the means ± S.E. for three separate experiments. A shows P3 (plasmid control, black-square), D1 (K215RGRK6-expressing, ), and GRK6 clone 24 (GRK6 overexpressing, ) cells. Similar data were obtained for P1 and D5 cells. [3H]Inositol phosphate accumulation was significantly (p < 0.01) greater and significantly reduced (p < 0.01) in cells that expressed K215RGRK6 or GRK6, respectively, compared with plasmid control cells.

M3 mACh Receptor Internalization-- To assess whether GRK6 mediated M3 mACh receptor internalization plasmid control, GRK6-overexpressing (clone 24) or K215RGRK6-expressing (D1) cells were exposed to MCh (100 µM) for up to 1 h. Subsequent [3H]NMS binding revealed that overexpression of GRK6 had no effect on M3 mACh receptor internalization. Furthermore, inhibition of endogenous GRK6 with K215RGRK6 failed to inhibit M3 mACh receptor internalization (Fig. 8).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 8.   Assessment of MCh-stimulated M3 mACh receptor internalization in plasmid control (P3, black-square), wt-GRK6-overexpressing (clone 24, ), or K215RGRK6-expressing (clone D1, ) cells. The cells were treated with either vehicle or MCh (100 µM) for 0-60 min, prior to extensive washing and subsequent [3H]NMS binding (5 nM) for 18 h at 4 °C. Nonspecific binding was determined in the presence of atropine (20 µM). Receptor internalization was determined as the percentage of loss of [3H]NMS-binding sites after MCh treatment when compared with vehicle-treated controls. The data are expressed as the means ± S.E. for three separate experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have recently shown that recombinant GRK6 can enhance both M3 mACh receptor phosphorylation and receptor/Galpha q/11 uncoupling, subsequently increasing desensitization of the endogenously expressed M3 mACh receptor in the SH-SY5Y neuroblastoma cell line (13). These data are suggestive of a role for endogenous GRK6 in the regulation of M3 mACh receptor desensitization. Therefore, in an attempt to block the action of endogenously expressed GRK6 in SH-SY5Y cells, we have introduced a kinase-dead, dominant-negative mutant, K215RGRK6.

Our data show for the first time the potential role of endogenous GRK6 in the regulation of an endogenously expressed Galpha q/11-coupled receptor. Despite the many studies indicating that GRKs are able to enhance the phosphorylation of overexpressed receptors (reviewed in Ref. 1), relatively few have examined the role of endogenous GRK6 activity in the regulation of endogenously expressed receptors. Introduction of antisense GRK6 oligonucleotides inhibited desensitization of the calcitonin gene-related peptide receptor stably expressed in HEK293 cells (20). However, several recent studies have reported the use of differing versions of dominant-negative GRK6 and have provided conflicting evidence as to their effectiveness in inhibiting endogenous GRK6. Lazari et al. (21) were able to inhibit endogenous GRK6 phosphorylation of follitrophin receptors in HEK293 cells by introducing a double point-mutated GRK6 (K215M/K216M). Zhou et al. (22) introduced a triple point-mutated (R215K/D484S/D485S) dominant-negative GRK6 that reduced agonist-stimulated thomboxane A2 receptor phosphorylation when compared with equivalent overexpression of GRK6 (22). However, unlike the present data, where we show a 50% reduction in agonist-stimulated M3 mACh receptor phosphorylation with expression of K215RGRK6, the action of endogenous GRK6 appeared not to be inhibited by this dominant-negative (R215K/D484S/D485SGRK6) (22). In view of these findings we chose to determine the catalytic activity of our dominant-negative GRK6 using immunoprecipitation of GFP-tagged GRK6 or K215RGRK6 and alpha -casein as substrate. These studies indicated that unlike wt-GRK6, K215RGRK6 was devoid of alpha -casein phosphorylating activity.

The finding that certain GRKs can mediate inhibition of PLC activity via nonreceptor phosphorylation mechanisms (23, 24) cautions against the use of dominant-negative GRKs. However, the ability of GRK2 and GRK3 to directly bind to activated, GTP-bound Galpha q/11 via their N-terminal RGS domain is not seen with GRK5 and GRK6 (23, 24). In addition, direct stimulation of PLC via activation of G proteins using AlF<UP><SUB>4</SUB><SUP>−</SUP></UP>, which is inhibited by GRK3 overexpression, was unaffected by either wt-GRK6 (13) or K215RGRK6. Nevertheless, to further examine the specificity of K215RGRK6 to inhibit M3 mACh receptor desensitization, we introduced the dominant-negative version of GRK5 (K215RGRK5). Interestingly, despite the close structural similarities between GRK5 and GRK6 (83.5% amino acid similarity for human forms of GRK5 and GRK6) (2), K215RGRK5 did not affect M3 mACh receptor signaling. This might seem surprising because both GRK5 and GRK6 are membrane-associated and thought to be regulated in a similar manner, i.e. negatively by calmodulin (25) and positively through phosphatidylinositol 4,5-biphosphate binding (26). In addition, evidence from GRK5 knockout mice suggests that GRK5 regulates many muscarinic responses attributable to M2 receptors in vivo (27). It is possible that the lack of effect of K215RGRK5 on M3 mACh receptor signaling in SH-SY5Y cells may reflect a lack of wt-GRK5. Although we were unable to detect endogenous GRK5 by Western blotting, immunoprecipitation studies from plasmid control SH-SY5Y cells indicated the presence of a GRK5 immunoprecipitable protein able to phosphorylate alpha -casein (data not shown). However, if the M3 mACh receptor was able to recruit GRK5, one might expect K215RGRK5 to block access of similar kinases to the receptor after agonist stimulation. The absence of this finding, combined with the inhibition of M3 mACh receptor phosphorylation by K215RGRK6, suggests that the recruitment signals for GRK5 or GRK6 are likely to be different even for these closely related kinases. It is also of interest that phosphorylation of the M3 mACh receptor by direct stimulation of PKC (by PDBu) was unaltered by the expression of K215RGRK6. All of these data imply that K215RGRK6-mediated inhibition of M3 mACh phosphorylation is not due to a nonspecific physical association of receptor and kinase but requires the specific recruitment of GRK6 by the receptor after agonist activation.

Because GRK6 appears to regulate M3 mACh receptor desensitization, it is interesting to speculate which phosphoacceptor sites GRK6 may phosphorylate. Despite the wealth of studies implicating GRK involvement in receptor desensitization, no consensus sequence has been agreed for GRK phosphorylation (3, 28, 29). Several studies have identified serine or threonine clusters as favored targets for GRK-mediated receptor phosphorylation (30, 31). Wu et al. (32) have mapped the phosphorylation sites for GRK2 to two such regions (331SSS333 and 348SASS351) in the third intracellular loop of the M3 mACh receptor. Recent evidence examining the phosphorylation profile of the B2 bradykinin receptor has indicated that GRK (2, 3, 5 or 6) phosphorylation is limited to three distinct serines situated in the C-terminal tail (33). Closer examination of the individual serine moieties highlighted distinct phosphorylation patterns between GRKs, raising the possibility that different GRKs may regulate different receptor signaling mechanisms. These data suggest that GRK6 and GRK2 M3 mACh receptor phosphorylation sites may not be mutually exclusive but that phosphorylation patterns may differ both temporally and positionally. However, it is also noteworthy that unlike for the bradykinin B2 receptor, determination of M3 mACh receptor phosphorylation patterns is potentially much more complex because of the presence of 36 serine and 16 threonine residues within the third intracellular loop alone. Nevertheless, we have previously shown that although GRK3 and GRK6 enhance M3 mACh receptor phosphorylation, only GRK6 mediates uncoupling of the receptor from Galpha q/11 (13). Furthermore, inhibition of endogenous GRK6 with a 30-fold excess of K215RGRK6 only produced a 50% decrease in M3 receptor phosphorylation and Galpha q/11 uncoupling. This finding could suggest either that increasing K215RGRK6 overexpression may further inhibit M3 mACh receptor phosphorylation and Galpha q/11 uncoupling or more likely that other kinases such as GRK2 or 3 may contribute to M3 mACh receptor desensitization in SH-SY5Y cells.

Many studies have reported that GRK overexpression not only leads to enhanced desensitization but also accelerated internalization of receptors (reviewed in Refs. 1 and 3). The present data indicate that although GRK6 is capable of desensitizing the M3 mACh receptor, it appears not to play a significant role in receptor internalization. This finding may appear surprising, but for some receptors kinase-mediated phosphorylation does not always enhance receptor internalization. Indeed, in agreement with our data, Lazari et al. (21) found that although dominant-negative GRK2 or GRK6 are equally capable of inhibiting follitropin receptor phosphorylation, only inhibition of GRK2-mediated phosphorylation prevents receptor internalization. Moreover, our data suggest that the potential pattern of phosphoacceptor sites that mediate M3 mACh desensitization and internalization may be different. The presence of GRK2, GRK3, CK1alpha , and PKCs in SH-SY5Y cells and their ability to phosphorylate the M3 mACh receptor (10-13, 32) raise the possibility that one or more of these kinases may be responsible for regulating M3 mACh receptor internalization. Indeed, recent preliminary studies have shown that dominant-negative CK1alpha inhibits M1 receptor internalization when concurrently overexpressed in HEK293 cells (34). Furthermore, we have shown that overexpression of GRK3 in SH-SY5Y cells (13), and others have reported that GRK2 in Chinese hamster ovary cells (35) enhanced M3 mACh receptor internalization. It will be interesting to examine which of these kinases plays a role in the internalization of the endogenously expressed M3 mACh receptor in SH-SY5Y cells and whether this is crucial for recruitment of adaptor proteins and initiating alternative signaling cascades.

In conclusion we have examined the potential role of endogenously expressed GRK6 in the desensitization of M3 mACh receptors in the human SH-SY5Y cell line. Introduction of a dominant-negative, catalytically inactive GRK6 (K215RGRK6) inhibited both agonist-stimulated M3 mACh receptor phosphorylation and receptor/Galpha q/11 uncoupling. Furthermore, K215RGRK6 expression partially reversed the time-related decay of agonist activation of PLC. In contrast, the closely related K215RGRK5 was unable to affect M3 mACh signaling in any way. Despite the obvious effects of GRK6 on M3 mACh receptor PLC-coupled signaling, manipulation of GRK6 activity had no effect on receptor internalization. Overall these data suggest that endogenous GRK6 regulates, at least in part, M3 mACh receptor desensitization in human SH-SY5Y neuroblastoma cells.

    ACKNOWLEDGEMENTS

We thank Dr. Eamonn Kelly (Department of Pharmacology, University of Bristol, Bristol, UK) for kindly donating the K215RGRK5 and K215RGRK6 constructs. We gratefully acknowledge the contribution of Dr. J. Parkinson, who made the GFP-tagged GRK6 and K215RGRK6 constructs.

    FOOTNOTES

* This work was supported by Wellcome Trust Grant 062495.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Cell Physiology and Pharmacology, University of Leicester, Maurice Shock Medical Sciences Bldg., University Rd., Leicester, LE1 9HN, UK. Tel.: 0116-252-3075; Fax: 0116-252-5045; E-mail: jmw23@le.ac.uk.

Published, JBC Papers in Press, February 20, 2002, DOI 10.1074/jbc.M111217200

    ABBREVIATIONS

The abbreviations used are: PKC, protein kinase C; GRK, G protein-coupled receptor kinase; mACh, muscarinic acetylcholine; MCh, methacholine; PLC, phospholipase C; PDBu, phorbol 12,13-dibutyrate; NMS, N-methylscopolamine; CK1alpha , casein kinase 1alpha ; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate; GFP, green fluorescent protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Bunemann, M., and Hosey, M. M. (1999) J. Physiol. 517, 5-23[Free Full Text]
2. Sterne-Marr, R., and Benovic, J. L. (1996) Vitam. Horm. 51, 193-234
3. Ferguson, S. S. G. (2001) Pharmacol. Rev. 53, 1-24[Abstract/Free Full Text]
4. Pitcher, J. A., Lohse, M., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1992) Biochemistry 31, 3193-3197[CrossRef][Medline] [Order article via Infotrieve]
5. Benovic, J. L., Pike, L. J., Cerione, R. A., Staniszewski, C., Yoshimasa, T., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1985) J. Biol. Chem. 260, 7094-7101[Abstract/Free Full Text]
6. Clark, R. B., Friedman, J., Dixon, R. A. F., and Strader, C. D. (1989) Mol. Pharmacol. 36, 343-348[Abstract]
7. Krupnick, J. G., and Benovic, J. L. (1998) Ann. Rev. Pharmacol. Toxicol. 38, 289-319[CrossRef][Medline] [Order article via Infotrieve]
8. Pitcher, J. A., Freedman, N. J., and Lefkowitz, R. J. (1998) Ann. Rev. Biochem. 67, 653-692[CrossRef][Medline] [Order article via Infotrieve]
9. Tobin, A. B., and Nahorski, S. R. (1993) J. Biol. Chem. 268, 9817-9823[Abstract/Free Full Text]
10. Willars, G. B., Muller-Esterl, W., and Nahorski, S. R. (1999) Am. J. Physiol. 277, C859-C869[Medline] [Order article via Infotrieve]
11. Bundey, R. A., and Nahorski, S. R. (2001) Br. J. Pharmacol. 134, 257-264[CrossRef][Medline] [Order article via Infotrieve]
12. Budd, D. C., McDonald, J. E., and Tobin, A. B. (2000) J. Biol. Chem. 275, 19667-19675[Abstract/Free Full Text]
13. Willets, J. M., Challiss, R. A. J., Kelly, E., and Nahorski, S. R. (2001) Mol. Pharmacol. 60, 321-330[Abstract/Free Full Text]
14. Tiruppathi, C., Yan, W., Sandoval, R., Naqvi, T., Pronin, A. N., Benovic, J. L., and Malik, A. B. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7440-7445[Abstract/Free Full Text]
15. Mundell, S. J., Luty, J. S., Willets, J. M., Benovic, J. L., and Kelly, E. (1998) Br. J. Pharmacol. 125, 347-356[CrossRef][Medline] [Order article via Infotrieve]
16. Willets, J. M., and Kelly, E. (2001) Eur. J. Pharmacol. 431, 133-141[CrossRef][Medline] [Order article via Infotrieve]
17. Challiss, R. A. J., Jenkinson, S., Mistry, R., Batty, I. H., and Nahorski, S. R. (1993) Neuroprotocols 3, 135-144
18. Barr, A. J., Brass, L. F., and Manning, D. R. (1998) J. Biol. Chem. 272, 2223-2229
19. Akam, E. C., Challiss, R. A. J., and Nahorski, S. R. (2001) Br. J. Pharmacol. 132, 950-958[CrossRef][Medline] [Order article via Infotrieve]
20. Aiyar, N., Disa, J., Dang, K., Pronin, A. N., Benovic, J. L., and Nambi, P. (2000) Eur. J. Pharmacol. 403, 1-7[CrossRef][Medline] [Order article via Infotrieve]
21. Lazari, M., Liu, X., Nakamura, K., Benovic, J. L., and Ascoli, M. (1999) Mol. Endocrinol. 13, 866-878[Abstract/Free Full Text]
22. Zhou, H., Yan, F., and Tai, H.-H. (2001) J. Pharmacol. Exp. Ther. 298, 1243-1251[Abstract/Free Full Text]
23. Carman, C. V., Parent, J.-L., Day, P. W., Pronin, A. N., Sternweis, P. M., Wedergaertner, P. B., Gilman, A. G., Benovic, J. L., and Kozasa, T. (1999) J. Biol. Chem. 274, 34483-34492[Abstract/Free Full Text]
24. Sallese, M., Mariggio, S., D'Urbano, E., Iacovelli, L., and De Blasi, A. (2000) Mol. Pharmacol. 57, 826-831[Abstract/Free Full Text]
25. Pronin, A. N., Satpaev, D. K., Slepak, V. Z., and Benovic, J. L. (1997) J. Biol. Chem. 272, 18273-18280[Abstract/Free Full Text]
26. Pitcher, J. A., Fredericks, Z. L., Stone, W. C., Premont, R. T., Stoffel, R. H., Koch, W. J., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 24907-24913[Abstract/Free Full Text]
27. Gainetdinov, R. R., Bohn, L. M., Walker, J. K., Laporte, S. A., Macrae, A. D., Caron, M. G., Lefkowitz, R. J., and Premont, R. T. (1999) Neuron 24, 1029-1036[CrossRef][Medline] [Order article via Infotrieve]
28. Fredericks, Z. L., Pitcher, J. A., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 13796-13803[Abstract/Free Full Text]
29. Seibold, A., January, B. G., Freidman, J., Hipkin, R. W., and Clark, R. B. (1998) J. Biol. Chem. 273, 7637-7642[Abstract/Free Full Text]
30. Pals-Rylaarsdam, R., and Hosey, M. M. (1997) J. Biol. Chem. 272, 14152-14158[Abstract/Free Full Text]
31. Maestes, D. C., Potter, R. M., and Prossnitz, E. R. (1999) J. Biol. Chem. 274, 29791-29795[Abstract/Free Full Text]
32. Wu, G., Bogatkevich, G. S., Mukhin, Y. V., Benovic, J. L., Hildebrandt, J. D., and Lanier, S. M. (2000) J. Biol. Chem. 275, 9026-9034[Abstract/Free Full Text]
33. Blaukat, A., Pizard, A., Breit, A., Wernstedt, C., Alhenec-Gelas, F., Muller-Esterl, W., and Dikic, I. (2001) J. Biol. Chem. 276, 40431-40440[Abstract/Free Full Text]
34. Kellerbauer, A., Krudewig, R., Langer, B., Jakobs, K. H., and van Koppen, C. J. (2001) Naunyn-Schmiedeberg's Arch. Pharmacol. 363 (suppl.), 72
35. Tsuga, H., Okuno, E., Kameyama, K., and Haga, T. (1998) J. Pharmacol. Exp. Ther. 284, 1218-1226[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J. Luo, J. M. Busillo, and J. L. Benovic
M3 Muscarinic Acetylcholine Receptor-Mediated Signaling Is Regulated by Distinct Mechanisms
Mol. Pharmacol., August 1, 2008; 74(2): 338 - 347.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. S. Braverman, A. S. Tibb, and M. R. Ruggieri Sr
M2 and M3 Muscarinic Receptor Activation of Urinary Bladder Contractile Signal Transduction. I. Normal Rat Bladder
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 869 - 874.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
P. A. Dabisch, D. B. Miller, S. A. Reutter, R. J. Mioduszewski, and S. A. Thomson
Miotic Tolerance to Sarin Vapor Exposure: Role of the Sympathetic and Parasympathetic Nervous Systems
Toxicol. Sci., June 1, 2005; 85(2): 1041 - 1047.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X.-R. Ren, E. Reiter, S. Ahn, J. Kim, W. Chen, and R. J. Lefkowitz
Different G protein-coupled receptor kinases govern G protein and {beta}-arrestin-mediated signaling of V2 vasopressin receptor
PNAS, February 1, 2005; 102(5): 1448 - 1453.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. S. Popova and M. M. Rasenick
Clathrin-mediated Endocytosis of m3 Muscarinic Receptors: ROLES FOR G{beta}